Codexis to Report Third Quarter 2024 Financial Results on October 31

Rhea-AI Summary

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, has announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, after market close. The company's management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the financial results and provide a business update.

Investors and interested parties can access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. For those who prefer to join by phone, the live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), using access ID #13726635.

REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.

Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.

About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule and nucleic acid therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com

Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com

FAQ

When will Codexis (CDXS) report its Q3 2024 financial results?

Codexis (CDXS) will report its third quarter 2024 financial results on Thursday, October 31, 2024, after the market closes.

How can investors access Codexis' (CDXS) Q3 2024 earnings call?

Investors can access Codexis' Q3 2024 earnings call via a live webcast on the Codexis Investor Relations website or by dialing 877-705-2976 (domestic) or 201-689-8798 (international) at 4:30 pm Eastern Time on October 31, 2024.

Will there be a replay available for Codexis' (CDXS) Q3 2024 earnings call?

Yes, a telephone replay of Codexis' Q3 2024 earnings call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), using access ID #13726635.

What is Codexis' (CDXS) primary business focus?

Codexis (CDXS) is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing.